Glypican-3, GPC3 recombinant protein
- Known as:
- Glypican-3, GPC3 Rec. protein
- Catalog number:
- BRP1021
- Product Quantity:
- 100 μg
- Category:
- -
- Supplier:
- Biospect
- Gene target:
- Glypican-3 GPC3 recombinant protein
Related genes to: Glypican-3, GPC3 recombinant protein
- Gene:
- GPC3 NIH gene
- Name:
- glypican 3
- Previous symbol:
- SDYS
- Synonyms:
- OCI-5, SGBS, SGBS1, SGB, DGSX
- Chromosome:
- Xq26.2
- Locus Type:
- gene with protein product
- Date approved:
- 1996-08-08
- Date modifiied:
- 2019-04-23
Related products to: Glypican-3, GPC3 recombinant protein
Related articles to: Glypican-3, GPC3 recombinant protein
- Intraoperative tumor boundary identification is essential for complete resection of hepatocellular carcinoma (HCC). Glypican-3 (GPC3) is a tumor-associated membrane antigen that is highly expressed in most HCCs but barely in livers. This study evaluated the feasibility of GPC3 as a tumor-specific imaging target and developed a GPC3-targeted fluorescent probe for intraoperative tumor boundary identification. - Source: PubMed
Publication date: 2026/09/11
Kanda ShuheiNishino HirotoYoh TomoakiOkura KeisukeKurimoto MakotoHori YutaroNishio TakahiroIwaisako KeikoOgiso SatoshiHatano Etsuro - Glypican-3 (GPC3) is highly expressed in hepatocellular carcinoma. A 72-year-old man with hepatitis B-related cirrhosis and rising alpha-fetoprotein had a small hepatic nodule on gadoxetic acid-enhanced MRI (EOB-MRI). The nodule enlarged on 3 consecutive EOB-MRI examinations during a 5-month follow-up but remained indeterminate for hepatocellular carcinoma. GPC3-targeted PET/MR showed intense uptake in the lesion and no extrahepatic disease, and hepatectomy confirmed moderately differentiated hepatocellular carcinoma with strong GPC3 expression. This case suggests the potential value of GPC3-targeted PET/MR for clarifying MRI-indeterminate early hepatocellular carcinoma. - Source: PubMed
Publication date: 2026/09/09
Hu WenzhuLi MengtingJiang DaweiCai XiongLan Xiaoli - Glypican-3 (GPC3), highly expressed in the most common liver cancer hepatocellular carcinoma (HCC) but absent from normal liver, represents an attractive tumor-selective target. We evaluated GPC3-targeted paired PET diagnostic and alpha particle therapeutic (radiotheranostic) agents in orthotopic models of liver cancer. - Source: PubMed
Publication date: 2026/09/09
Lee WoongheeChung Joon-YongAdler StephenBasuli FalguniBaidoo KwamenaShi JianfengUeda YukiOmiya SatoshiNambiar DivyaMakala HimaSheehan-Klenk JuliaFayn StanleyOlkowski Colleen PKing A PadenRuf BenjaminGreten Tim FJacobson OritChoyke Peter LEscorcia Freddy E - Chimeric antigen receptor (CAR) T-cell therapies have shown limited promise in solid tumors owing to the immunosuppressive tumor microenvironment. TAK-102 is a next-generation, glypican-3 (GPC3)-targeted CAR T-cell therapy engineered to co-express interleukin-7 (IL-7) and chemokine ligand 19 (CCL19), enhancing T-cell survival and trafficking. In this first-in-human, open-label, phase 1, dose-escalation study (ClinicalTrials.gov: NCT04405778), we evaluated a single TAK-102 infusion in 11 patients with GPC3+ advanced solid tumors refractory or intolerant to standard therapies. Patients received TAK-102 at one of three dose levels following leukapheresis and lymphodepletion chemotherapy. The primary endpoints were the incidences of dose-limiting toxicities, treatment-emergent adverse events, and adverse events of special interest. No dose-limiting toxicities were observed. The most common treatment-emergent adverse events were hematologic, including neutropenia and leukopenia (81.8%), and cytokine release syndrome (54.5%), all grade 1-2. No objective responses were observed; however, five patients achieved stable disease (disease control rate, 45.5%). One patient had a 26.1% reduction in tumor size lasting 9 months, accompanied by a 51.6% decline in serum alpha-fetoprotein. Cellular kinetics showed dose-dependent expansion, with the highest exposure at 5 × 10⁸ CAR+ cells/body. Post-treatment biopsies revealed increased CD8+ T-cell infiltration and activation markers, although CAR+ cells were undetectable in tumor tissue. Serum CCL19 levels increased with dose, suggesting immune priming. These findings support a manageable safety profile for TAK-102 and provide early evidence of biological activity in solid tumors. Further studies are warranted to optimize dosing, improve CAR T-cell persistence, and evaluate efficacy in larger patient cohorts. - Source: PubMed
Publication date: 2026/09/08
Kuboki YasutoshiKoyama TakafumiIkeda MasafumiSatake TomoyukiSawada TakeshiShimazu YutakaKondo ShunsukeKatsuya YukiKagehara HideakiAkaike TakenoriSingh AmanAtkuri KondalaPop-Damkov PetarTamada KojiNakajima Takako Eguchi - Identifying tumor selective targets is critical for the development of precision diagnostic and therapeutic agents in oncology. Despite advances in precision oncology elsewhere, there are no FDA-approved hepatocellular carcinoma (HCC) antigen-selective antibody-drug conjugates or radiopharmaceuticals. This study establishes an integrated workflow to identify HCC-enriched plasma membrane targets and assess their suitability for targeted molecular imaging as foundational candidates for future radiopharmaceutical therapy. - Source: PubMed
Publication date: 2026/07/29
Homan PhilipChung Joon-YongLee WoongheeNambiar DivyaSheehan-Klenk JuliaMakala HimaFayn StanleyJacobson OritKing Arthur PadenKim KyungeunKim Jeong WonLee Sung RyolCam MaggieHewitt Stephen MWang Xin WeiHo MitchellEscorcia Freddy E